Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Still More To Be Done On European Biosimilars

Medicines For Europe Releases Latest Biosimilar Market Review Report

Executive Summary

Off-patent industry association Medicines for Europe has released a Biosimilar Market Review report that examines availability, pricing systems, retail markets, hospital tendering, reimbursement systems, healthcare practitioner-related policies, information and education around biosimilars in 26 European countries, concluding that “while progress has been made, it is clear much more can be done.” 

You may also be interested in...



Biosimilars Must Play Key Role In EU Pharma Strategy

European policy makers must act quickly to harness the benefits of biosimilars as part of the new EU Pharma Strategy, Medicines for Europe insists in the wake of the latest annual report on European biosimilar competition.

EU Pharma Strategy Will Remove Barriers And Bolster Competition

The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.

European Industry Backs Biosimilars ‘Scorecards’

Medicines for Europe and IQVIA have partnered to test biosimilar sustainability in 12 European countries by issuing scorecards that measure the contribution of a country’s biosimilar policies to health systems.

Topics

UsernamePublicRestriction

Register

GB150799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel